Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 1846127Generated: November 3, 2026

Hydrogen Bromide → 6,7-Dihydroxy-4(3H)-quinazolinone

https://huagongshe.com/reaction/1846127

Reaction equation

Participants

RoleNameHCIDCharge
ReactantHydrogen BromideHCID 260—
ReactantErlotinib HydrochlorideHCID 176871—
ReactantPyridinium chlorideHCID 10176127—
Reactant6,7-Dimethoxy-3H-quinazolin-4-oneHCID 135495016—
Product6,7-Dihydroxy-4(3H)-quinazolinoneHCID 135742258—

Reaction Steps

A method for the preparation of erlotinib hydrochloride was disclosed in US 2009/0306377. The method, illustrated in Scheme 2, involves treating 6,7-dimethoxy-4(3H)-quinazolone (5) with hydrobromic acid or pyridine-hydrochloric acid to afford 6,7-dihydroxy-4(3H)-quinazolone (6), which was diacetylated with acetic anhydride to afford diester (7), which was treated with oxalyl chloride/DMF to afford 4-chloro-6,7-diacetoxyquinazoline (8). Compound (8) was condensed with 3-ethynylaniline to afford N-(3-ethynylphenyl)-6,7-dihydroxy-4-quinazolinamine hydrochloride (9), which was converted into the diol N-(3-ethynylphenyl)-6,7-dihydroxy-4-quinazolinamine (10) by treatment with aqueous ammonia/methanol. The diol (10) was treated with 2-iodo-ethylmethyl ether to yield compound (4) which on treatment with HCl afforded erlotinib hydrochloride (1). However, this preparation of erlotinib hydrochloride is a long synthetic route and gives low yields and requires very toxic reagents like pyridine, HBr and controlled reagents like acetic anhydride. Hence, it is not suitable for large scale production.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS08952022B2
Source datasetuspto-grants-2015_02
ORD IDord-5fd7229cec7049f6bfe2864588b6348e
Source noteuspto-grants-2015_02